Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00448292
Status:
COMPLETED
Last Update Posted:
2007-11-14
First Post:
2007-03-13
Brief Title:
A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
Sponsor:
Epix Pharmaceuticals Inc
Organization:
Epix Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Study of the Efficacy of PRX-00023 in Patients With Major Depressive Disorder
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this randomized double-blind placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder
Detailed Description:
Patients with major depressive disorder who meet all of the eligibility criteria will be randomly assigned to receive twice daily doses of either placebo or PRX-00023 Study drug will be taken for up to approximately 9 weeks Patients will have periodic office visits for the purpose of monitoring safety and tolerability as well as efficacy assessments
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None